PUBLISHER: Acute Market Reports | PRODUCT CODE: 1642607
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1642607
Breast Cancer Liquid Biopsy Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
The breast cancer liquid biopsy market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032. Breast cancer liquid biopsy market is a rapidly evolving field that utilizes non-invasive liquid biopsies to detect and monitor breast cancer through blood samples. This method offers a significant advancement over traditional tissue biopsies, providing real-time insights into tumor dynamics and allowing for personalized treatment strategies. The technology's potential to revolutionize cancer detection and management has positioned it at the forefront of oncology research and clinical application.
Drivers
Advancements in Genomic Technologies
Technological advancements in genomic sequencing and analysis have been pivotal in driving the breast cancer liquid biopsy market. As next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques have become more sophisticated, they offer deeper insights into the genetic basis of breast cancer, enabling the detection of minute quantities of tumor DNA in the bloodstream. These advancements have not only enhanced the sensitivity and specificity of liquid biopsies but have also broadened their potential applications, including early detection, prognosis, and monitoring of therapeutic efficacy and resistance. The continuous improvements in genomic technologies underscore their role in the growing adoption of liquid biopsies in clinical settings.
Growing Demand for Non-Invasive Procedures
The increasing preference for non-invasive diagnostic procedures among both patients and healthcare providers is another significant driver for the breast cancer liquid biopsy market. Traditional tissue biopsies, while effective, are invasive and often lead to discomfort and potential complications. In contrast, liquid biopsies offer a minimally invasive alternative that can be performed with a simple blood draw, reducing patient stress and risk. This patient-friendly approach is particularly advantageous for repeated testing required in monitoring tumor progression and response to treatment, making liquid biopsies an attractive option for continuous disease management.
Rising Prevalence of Breast Cancer
The rising global prevalence of breast cancer significantly fuels the demand for effective diagnostic and monitoring tools, boosting the liquid biopsy market. With breast cancer being one of the most common cancers worldwide, there is an urgent need for advancements in diagnostic techniques that can lead to earlier detection and improved patient outcomes. Liquid biopsies meet this need by providing a tool that can detect cancer at its earliest stages from a blood sample, facilitating timely intervention and personalized treatment plans. The increasing incidence of breast cancer globally is a compelling driver for the development and adoption of liquid biopsy solutions.
Restraint
Regulatory and Reimbursement Challenges
Despite the potential and growth of the breast cancer liquid biopsy market, it faces significant restraints with regulatory and reimbursement challenges. The novelty and complexity of liquid biopsy tests pose hurdles in gaining regulatory approvals from bodies like the FDA, as these agencies require extensive validation of the tests' clinical utility and accuracy before they can be broadly implemented. Furthermore, the lack of standardized guidelines for the use and interpretation of liquid biopsies adds to the regulatory challenges. On the reimbursement front, insufficient coverage and unclear reimbursement policies for liquid biopsies can deter healthcare providers from adopting this technology, as the financial costs of these advanced tests are often higher than traditional methods. These regulatory and reimbursement issues are substantial obstacles that slow the market's growth and widespread adoption.
Market Segmentation by Biomarkers
The breast cancer liquid biopsy market is segmented by biomarkers, including Circulating Tumor Cells (CTCs), Cell-free DNA (cfDNA), Exosomes, and Other Biomarkers. Among these, cfDNA leads in revenue generation due to its high clinical utility in detecting and monitoring minimal residual disease and treatment resistance. Its ability to provide rapid, non-invasive insights into tumor genetics makes cfDNA a preferred choice in clinical settings. Furthermore, cfDNA is projected to exhibit the highest Compound Annual Growth Rate (CAGR) over the forecast period, driven by continuous advancements in sequencing technologies and increasing clinical adoption. On the other hand, CTCs also play a crucial role, particularly in understanding metastatic processes, though they capture a smaller portion of the market due to the technical challenges associated with their isolation and analysis. Exosomes are gaining traction as they provide comprehensive molecular information that potentially offers insights into tumor behavior and response to therapy. The segment of Other Biomarkers, which includes proteins and metabolites, shows promise due to ongoing research and potential to complement existing biomarkers for a more detailed disease profiling and treatment efficacy evaluation.
Market Segmentation by Products & Services
In the breast cancer liquid biopsy market, segmentation by Products & Services includes Kits & Reagents and Services. Kits & Reagents dominate in terms of revenue, as they are the foundational components used in liquid biopsy tests. This segment benefits from the frequent consumption and recurring purchases associated with liquid biopsy procedures, which involve multiple stages of testing over a patient's treatment course. Additionally, the ongoing innovation in reagents and kits, aimed at enhancing accuracy and efficiency, supports their high revenue generation. Meanwhile, Services are expected to witness the highest CAGR. This growth is fueled by the increasing preference for comprehensive service offerings that include test execution, data analysis, and actionable insights, which are highly valued in clinical settings for making informed treatment decisions. The rise in specialized diagnostic services and the expansion of laboratory capabilities to accommodate advanced liquid biopsy technologies contribute significantly to the growth of this segment.
Geographic Trends
The breast cancer liquid biopsy market demonstrates dynamic geographic trends, with North America currently leading in terms of revenue due to its advanced healthcare infrastructure, high awareness about cancer screenings, and the presence of key market players. However, Asia-Pacific is expected to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2032, driven by rising healthcare expenditures, increasing patient awareness, and improving healthcare facilities. The growing prevalence of breast cancer in countries like China and India, coupled with increasing investments in healthcare technologies, fuels the rapid growth in this region. Europe also maintains a significant share in the market, supported by its strong regulatory frameworks for cancer diagnostics and substantial healthcare spending.
Competitive Trends
In terms of competitive trends, the market sees robust participation from companies like Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, QIAGEN, Sysmex, System Biosciences, Thermo Fisher Scientific, and Twist Bioscience. These entities have leveraged various strategies to solidify their market positions and expand their revenue streams. In 2022, these companies reported substantial revenues, reflecting their dominance and innovative capabilities within the market. Their strategies for the forecast period of 2024 to 2032 are expected to focus on technological innovations, mergers and acquisitions, and geographic expansion. For instance, many of these firms are enhancing their product lines with integrations of advanced genomic technologies to increase the accuracy and reliability of liquid biopsies. Partnerships and collaborations are also crucial as companies aim to expand their global footprints, particularly in untapped markets within Asia-Pacific and Latin America. Moreover, investment in research and development is a key strategy for these companies, aiming to lead in the discovery of novel biomarkers and improve the sensitivity of existing liquid biopsy techniques. These strategic efforts are anticipated to drive the continued growth and competitive edge of these companies in the upcoming years, aligning with the overall expansion trends seen across the global market.
Historical & Forecast Period
This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Breast Cancer Liquid Biopsy market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Breast Cancer Liquid Biopsy market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
- Market Segmentation
- Biomarkers
- Circulating tumor cells (CTCs)
- Cell-free DNA (cfDNA)
- Exosomes
- Other biomarkers
- Products & Services
- Kits & reagents
- Services
- Sample Type
- Blood
- Urine
- Other sample types
- End Use
- Hospitals
- Cancer research centers
- Diagnostic centers
- Academic and research institutes
- Region Segment (2022-2032; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Liquid Biopsy market?
- What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2032.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Breast Cancer Liquid Biopsy market?
- Which is the largest regional market for Breast Cancer Liquid Biopsy market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Breast Cancer Liquid Biopsy market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Liquid Biopsy market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Breast Cancer Liquid Biopsy Market
- 2.2. Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 (US$ Million)
- 2.3. Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 (US$ Million)
- 2.4. Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 (US$ Million)
- 2.5. Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 (US$ Million)
- 2.6. Global Breast Cancer Liquid Biopsy Market, By Geography, 2023 (US$ Million)
- 2.7. Attractive Investment Proposition by Geography, 2023
3. Breast Cancer Liquid Biopsy Market: Competitive Analysis
- 3.1. Market Positioning of Key Breast Cancer Liquid Biopsy Market Vendors
- 3.2. Strategies Adopted by Breast Cancer Liquid Biopsy Market Vendors
- 3.3. Key Industry Strategies
4. Breast Cancer Liquid Biopsy Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Breast Cancer Liquid Biopsy Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Market Segmentation
- 5.3.1. Circulating tumor cells (CTCs)
- 5.3.2. Cell-free DNA (cfDNA)
- 5.3.3. Exosomes
- 5.3.4. Other biomarkers
6. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Market Segmentation
- 6.3.1. Kits & reagents
- 6.3.2. Services
7. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2023 Versus 2032
- 7.3. Market Segmentation
- 7.3.1. Blood
- 7.3.2. Urine
- 7.3.3. Other sample types
8. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Growth & Revenue Analysis: 2023 Versus 2032
- 8.3. Market Segmentation
- 8.3.1. Hospitals
- 8.3.2. Cancer research centers
- 8.3.3. Diagnostic centers
- 8.3.4. Academic and research institutes
9. North America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 9.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 9.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 9.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 9.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 9.6.1.North America
- 9.6.1.1. U.S.
- 9.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 9.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 9.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 9.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 9.6.1.2. Canada
- 9.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 9.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 9.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 9.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 9.6.1.3. Rest of North America
- 9.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 9.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 9.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 9.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 9.6.1.1. U.S.
- 9.6.1.North America
10. UK and European Union Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 10.6.1.UK and European Union
- 10.6.1.1. UK
- 10.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.2. Germany
- 10.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.3. Spain
- 10.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.4. Italy
- 10.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.5. France
- 10.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.6. Rest of Europe
- 10.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 10.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 10.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 10.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 10.6.1.1. UK
- 10.6.1.UK and European Union
11. Asia Pacific Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 11.6.1.Asia Pacific
- 11.6.1.1. China
- 11.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.2. Japan
- 11.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.3. India
- 11.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.4. Australia
- 11.6.1.4.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.4.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.4.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.4.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.5. South Korea
- 11.6.1.5.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.5.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.5.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.5.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.6. Rest of Asia Pacific
- 11.6.1.6.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 11.6.1.6.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 11.6.1.6.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 11.6.1.6.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 11.6.1.1. China
- 11.6.1.Asia Pacific
12. Latin America Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)
- 12.1. Market Overview
- 12.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 12.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 12.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 12.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 12.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 12.6.1.Latin America
- 12.6.1.1. Brazil
- 12.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 12.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 12.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 12.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 12.6.1.2. Mexico
- 12.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 12.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 12.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 12.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 12.6.1.3. Rest of Latin America
- 12.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 12.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 12.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 12.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 12.6.1.1. Brazil
- 12.6.1.Latin America
13. Middle East and Africa Breast Cancer Liquid Biopsy Market, 2022-2032, USD (Million)
- 13.1. Market Overview
- 13.2. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 13.3. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 13.4. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 13.5. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 13.6.Breast Cancer Liquid Biopsy Market: By Region, 2022-2032, USD (Million)
- 13.6.1.Middle East and Africa
- 13.6.1.1. GCC
- 13.6.1.1.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 13.6.1.1.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 13.6.1.1.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 13.6.1.1.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 13.6.1.2. Africa
- 13.6.1.2.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 13.6.1.2.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 13.6.1.2.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 13.6.1.2.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 13.6.1.3. Rest of Middle East and Africa
- 13.6.1.3.1. Breast Cancer Liquid Biopsy Market: By Biomarkers, 2022-2032, USD (Million)
- 13.6.1.3.2. Breast Cancer Liquid Biopsy Market: By Products & Services, 2022-2032, USD (Million)
- 13.6.1.3.3. Breast Cancer Liquid Biopsy Market: By Sample Type, 2022-2032, USD (Million)
- 13.6.1.3.4. Breast Cancer Liquid Biopsy Market: By End Use, 2022-2032, USD (Million)
- 13.6.1.1. GCC
- 13.6.1.Middle East and Africa
14. Company Profile
- 14.1. Datar Cancer Genetics
- 14.1.1. Company Overview
- 14.1.2. Financial Performance
- 14.1.3. Product Portfolio
- 14.1.4. Strategic Initiatives
- 14.2. Epic Sciences
- 14.2.1. Company Overview
- 14.2.2. Financial Performance
- 14.2.3. Product Portfolio
- 14.2.4. Strategic Initiatives
- 14.3. F. Hoffmann-La Roche
- 14.3.1. Company Overview
- 14.3.2. Financial Performance
- 14.3.3. Product Portfolio
- 14.3.4. Strategic Initiatives
- 14.4. Genes2me
- 14.4.1. Company Overview
- 14.4.2. Financial Performance
- 14.4.3. Product Portfolio
- 14.4.4. Strategic Initiatives
- 14.5. Illumina
- 14.5.1. Company Overview
- 14.5.2. Financial Performance
- 14.5.3. Product Portfolio
- 14.5.4. Strategic Initiatives
- 14.6. Menarini Silicon Biosystems
- 14.6.1. Company Overview
- 14.6.2. Financial Performance
- 14.6.3. Product Portfolio
- 14.6.4. Strategic Initiatives
- 14.7. Myriad Genetics
- 14.7.1. Company Overview
- 14.7.2. Financial Performance
- 14.7.3. Product Portfolio
- 14.7.4. Strategic Initiatives
- 14.8. OncoDNA
- 14.8.1. Company Overview
- 14.8.2. Financial Performance
- 14.8.3. Product Portfolio
- 14.8.4. Strategic Initiatives
- 14.9. QIAGEN
- 14.9.1. Company Overview
- 14.9.2. Financial Performance
- 14.9.3. Product Portfolio
- 14.9.4. Strategic Initiatives
- 14.10. Sysmex
- 14.10.1. Company Overview
- 14.10.2. Financial Performance
- 14.10.3. Product Portfolio
- 14.10.4. Strategic Initiatives
- 14.11. System Biosciences
- 14.11.1. Company Overview
- 14.11.2. Financial Performance
- 14.11.3. Product Portfolio
- 14.11.4. Strategic Initiatives
- 14.12. Thermo Fisher Scientific
- 14.12.1. Company Overview
- 14.12.2. Financial Performance
- 14.12.3. Product Portfolio
- 14.12.4. Strategic Initiatives
- 14.13. Twist Bioscience
- 14.13.1. Company Overview
- 14.13.2. Financial Performance
- 14.13.3. Product Portfolio
- 14.13.4. Strategic Initiatives
- 14.14. Other Notable Players
- 14.14.1. Company Overview
- 14.14.2. Financial Performance
- 14.14.3. Product Portfolio
- 14.14.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 2 Global Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 3 Global Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 4 Global Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 5 North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 6 North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 7 North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 8 North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 9 U.S. Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 10 U.S. Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 11 U.S. Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 12 U.S. Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 13 Canada Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 14 Canada Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 15 Canada Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 16 Canada Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 17 Rest of North America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 18 Rest of North America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 19 Rest of North America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 20 Rest of North America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 21 UK and European Union Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 22 UK and European Union Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 23 UK and European Union Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 24 UK and European Union Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 25 UK Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 26 UK Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 27 UK Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 28 UK Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 29 Germany Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 30 Germany Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 31 Germany Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 32 Germany Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 33 Spain Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 34 Spain Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 35 Spain Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 36 Spain Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 37 Italy Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 38 Italy Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 39 Italy Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 40 Italy Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 41 France Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 42 France Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 43 France Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 44 France Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 45 Rest of Europe Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 46 Rest of Europe Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 47 Rest of Europe Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 48 Rest of Europe Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 49 Asia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 50 Asia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 51 Asia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 52 Asia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 53 China Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 54 China Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 55 China Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 56 China Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 57 Japan Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 58 Japan Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 59 Japan Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 60 Japan Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 61 India Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 62 India Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 63 India Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 64 India Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 65 Australia Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 66 Australia Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 67 Australia Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 68 Australia Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 69 South Korea Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 70 South Korea Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 71 South Korea Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 72 South Korea Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 73 Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 74 Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 75 Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 76 Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 77 Brazil Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 78 Brazil Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 79 Brazil Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 80 Brazil Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 81 Mexico Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 82 Mexico Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 83 Mexico Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 84 Mexico Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 85 Rest of Latin America Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 86 Rest of Latin America Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 87 Rest of Latin America Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 88 Rest of Latin America Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 89 Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 90 Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 91 Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 92 Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 93 GCC Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 94 GCC Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 95 GCC Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 96 GCC Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 97 Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 98 Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 99 Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 100 Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
- TABLE 101 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Biomarkers, 2022-2032, USD (Million)
- TABLE 102 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Products & Services, 2022-2032, USD (Million)
- TABLE 103 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By Sample Type, 2022-2032, USD (Million)
- TABLE 104 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market By End Use, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Breast Cancer Liquid Biopsy Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Breast Cancer Liquid Biopsy Market: Quality Assurance
- FIG. 5 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023
- FIG. 6 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023
- FIG. 7 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023
- FIG. 8 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023
- FIG. 9 Global Breast Cancer Liquid Biopsy Market, By Geography, 2023
- FIG. 10 Market Geographical Opportunity Matrix - Global Breast Cancer Liquid Biopsy Market, 2023
- FIG. 11Market Positioning of Key Breast Cancer Liquid Biopsy Market Players, 2023
- FIG. 12Global Breast Cancer Liquid Biopsy Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 13 Global Breast Cancer Liquid Biopsy Market, By Biomarkers, 2023 Vs 2032, %
- FIG. 14 Global Breast Cancer Liquid Biopsy Market, By Products & Services, 2023 Vs 2032, %
- FIG. 15 Global Breast Cancer Liquid Biopsy Market, By Sample Type, 2023 Vs 2032, %
- FIG. 16 Global Breast Cancer Liquid Biopsy Market, By End Use, 2023 Vs 2032, %
- FIG. 17 U.S. Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 18 Canada Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 19 Rest of North America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 20 UK Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 21 Germany Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 22 Spain Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 23 Italy Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 24 France Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 25 Rest of Europe Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 26 China Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 27 Japan Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 28 India Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 29 Australia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 30 South Korea Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 31 Rest of Asia Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 32 Brazil Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 33 Mexico Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 34 Rest of Latin America Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 35 GCC Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 36 Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
- FIG. 37 Rest of Middle East and Africa Breast Cancer Liquid Biopsy Market (US$ Million), 2022 - 2032
